10-Q · May 7, 2026
Aardvark Therapeutics reported a net loss of $21.6 million for Q1 2026 with no revenue, remaining consistent with the previous quarter's performance. The company faced increased R&D costs and announced a voluntary pause…
Earnings analysis · 10-Q
AARD earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Aardvark’s Q2 2026 diluted EPS of -$0.66 improved from -$0.99 sequentially but remained unchanged year over year, while revenue, margins and current-quarter free cash flow were not disclosed in the provided filing text.…
Read full summary
Aardvark’s Q2 2026 diluted EPS of -$0.66 improved from -$0.99 sequentially but remained unchanged year over year, while revenue, margins and current-quarter free cash flow were not disclosed in the provided filing text. The company has approximately $73.9 million of liquidity and expects runway into late 2027, but the FDA’s full clinical hold, termination of the HERO and OLE trials, and six-month net loss growth to $36.0 million from $23.7 million materially weaken the outlook. Management expects to provide further ARD-101 guidance in Q3 2026, but no quantitative revenue or EPS guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.66
What stood out
-
EPS Improved Sequentially
Diluted EPS was -$0.66 in Q2 2026, improving from -$0.99 in Q1 2026 but unchanged from -$0.66 in Q2 2025.
-
Cash Runway Into Late 2027
Cash, cash equivalents and short-term investments totaled approximately $73.9 million as of June 30, 2026, which management expects to fund projected operations into late 2027.
-
Effective Disclosure Controls
Disclosure controls and procedures were concluded effective as of June 30, 2026, and the company reported no changes in internal control that materially affected, or were reasonably likely to materially affect, reporting controls.
-
Financing Capacity Available
The company has access to an effective shelf registration permitting equity and debt offerings of up to $400.0 million, while its $150.0 million ATM facility had no sales as of June 30, 2026.
What to watch
-
ARD-101 Clinical Program Disrupted
The FDA placed a full clinical hold on the ARD-101 IND in May 2026, and the company terminated both the HERO and OLE trials in June 2026; it does not currently intend to resume them as previously designed.
-
Losses Expanded Materially
The company reported a six-month net loss of $36.0 million for 2026 versus $23.7 million for 2025, and had an accumulated deficit of $151.9 million as of June 30, 2026.
-
Future Financing Required
Management states that substantial additional financing will be required, despite approximately $73.9 million of liquidity projected to fund operations into late 2027; the company may need capital sooner if its operating assumptions change.
-
Lean Workforce May Limit Execution
The Q2 workforce reduction was implemented after the clinical hold, and the company had only 28 employees and 27 full-time or part-time consultants as of July 31, 2026, raising execution and retention risks.
-
Stronger Competitive Position
Neurocrine acquired Soleno in May 2026, potentially strengthening the commercial position of VYKAT XR, the only approved treatment for PWS-associated hyperphagia, against ARD-101.
-
Dilution and Financing Risk
The company has an ATM facility for up to $150.0 million and a shelf registration for up to $400.0 million of equity and debt securities; future offerings could dilute existing stockholders or add repayment obligations.
Management's outlook
No revenue or EPS guidance was provided. Management said approximately $73.9 million of cash, cash equivalents and short-term investments as of June 30, 2026 is expected to fund projected operations into late 2027, and expects to provide further guidance on ARD-101 in the third quarter of 2026.
Earlier filings 3
10-K · March 23, 2026
Aardvark is a clinical-stage biotech focused on gut-restricted TAS2R agonists (lead: ARD-101) for hunger-associated disorders. The company advanced ARD-101 into a Phase 3 HERO trial (initiated Dec 2024) and had >50% of…
10-Q · November 13, 2025
Aardvark reported a Q3 net loss of $16.3M (net loss per share $0.75) driven by a ramp in R&D and G&A as the company advances ARD-101. Liquidity materially improved following the February 2025 IPO (cash and short-term…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.